TROP2 confers resistance to oxidative stress-induced cancer cell death through YAP/HMOX1 signaling.
[BACKGROUND] Trophoblast cell surface antigen 2 (TROP2) is overexpressed in non-small cell lung cancer (NSCLC) and associated with poor prognosis, yet its role in ferroptosis—an iron-dependent form of
APA
Wu D, Liu Y, et al. (2026). TROP2 confers resistance to oxidative stress-induced cancer cell death through YAP/HMOX1 signaling.. Journal of translational medicine, 24(1). https://doi.org/10.1186/s12967-026-07955-z
MLA
Wu D, et al.. "TROP2 confers resistance to oxidative stress-induced cancer cell death through YAP/HMOX1 signaling.." Journal of translational medicine, vol. 24, no. 1, 2026.
PMID
41814370
Abstract
[BACKGROUND] Trophoblast cell surface antigen 2 (TROP2) is overexpressed in non-small cell lung cancer (NSCLC) and associated with poor prognosis, yet its role in ferroptosis—an iron-dependent form of regulated cell death—remains largely unknown. This study investigated the function and underlying mechanism of TROP2 in ferroptosis regulation in lung cancer.
[METHODS] TROP2 expression was examined in NSCLC tissues and cell lines. Functional assays, including RNA sequencing, qRT-PCR, Western blot, flow cytometry, and transmission electron microscopy, were performed in lung cancer cells with TROP2 knockdown or overexpression. The involvement of the YAP1/HMOX1 axis was evaluated using luciferase reporter assays, immunofluorescence, and nuclear-cytoplasmic fractionation. An in vivo xenograft model was established to assess the effect of TROP2 inhibition combined with the ferroptosis inducer RSL3.
[RESULTS] TROP2 was significantly upregulated in NSCLC tissues and correlated with worse patient survival. Knockdown of TROP2 sensitized cells to RSL3-induced ferroptosis, as evidenced by increased lipid peroxidation, reactive oxygen species, and malondialdehyde levels, along with reduced glutathione. Mechanistically, TROP2 inhibited nuclear translocation of YAP1, which consequently suppressed transcriptional activation of the key ferroptosis-promoting gene HMOX1. Rescue experiments confirmed that HMOX1 mediates the pro-ferroptotic effect of TROP2 knockdown. In vivo, TROP2 depletion synergized with RSL3 to suppress tumor growth and elevate ferroptosis markers.
[CONCLUSION] TROP2 confers ferroptosis resistance in NSCLC by inhibiting YAP1 nuclear translocation and subsequent HMOX1 transcription. Targeting TROP2 sensitizes lung cancer cells to ferroptosis inducers, revealing a novel TROP2/YAP1/HMOX1 regulatory axis with therapeutic potential for NSCLC treatment.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12967-026-07955-z.
[METHODS] TROP2 expression was examined in NSCLC tissues and cell lines. Functional assays, including RNA sequencing, qRT-PCR, Western blot, flow cytometry, and transmission electron microscopy, were performed in lung cancer cells with TROP2 knockdown or overexpression. The involvement of the YAP1/HMOX1 axis was evaluated using luciferase reporter assays, immunofluorescence, and nuclear-cytoplasmic fractionation. An in vivo xenograft model was established to assess the effect of TROP2 inhibition combined with the ferroptosis inducer RSL3.
[RESULTS] TROP2 was significantly upregulated in NSCLC tissues and correlated with worse patient survival. Knockdown of TROP2 sensitized cells to RSL3-induced ferroptosis, as evidenced by increased lipid peroxidation, reactive oxygen species, and malondialdehyde levels, along with reduced glutathione. Mechanistically, TROP2 inhibited nuclear translocation of YAP1, which consequently suppressed transcriptional activation of the key ferroptosis-promoting gene HMOX1. Rescue experiments confirmed that HMOX1 mediates the pro-ferroptotic effect of TROP2 knockdown. In vivo, TROP2 depletion synergized with RSL3 to suppress tumor growth and elevate ferroptosis markers.
[CONCLUSION] TROP2 confers ferroptosis resistance in NSCLC by inhibiting YAP1 nuclear translocation and subsequent HMOX1 transcription. Targeting TROP2 sensitizes lung cancer cells to ferroptosis inducers, revealing a novel TROP2/YAP1/HMOX1 regulatory axis with therapeutic potential for NSCLC treatment.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12967-026-07955-z.
같은 제1저자의 인용 많은 논문 (5)
- Ga-pentixafor PET/CT shows better diagnostic performance than F-FDG PET/CT in chronic lymphocytic leukemia/small lymphocytic lymphoma: a case report and review of literature.
- Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition.
- SPHK1 deficiency promotes intestinal homeostasis by ameliorating ER stress-induced gastrointestinal injury during murine graft-versus-host disease.
- Pyroptosis as a molecular bridge: linking gasdermin activation to enhanced anti-tumor immunity in immunotherapy.
- Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non-Small Cell Lung Cancer.